Head-to-head evidence
SYHX1901 vs TQH3906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
SYHX1901
Developed by CSPC Ouyi Pharmaceutical Co. and partners
NCT05858047 · Phase 2 · completed
The trial randomized 93 participants to placebo or one of three SYHX1901 doses and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical PASI 75 response at week 12, but no results are available to determine whether the comparison was met.
Next expected readout: April 2027 · NCT06943950 (registry estimate)
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SYHX1901's landscape · TQH3906's landscape